Saturday 17 October 2026
Export IRMD’s income statement to Excel — free account
iRadimed Corporation
IRMD Healthcare Medical Devices
iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 8.89% and free cash flow grew 11.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
88.27
1.10
−1.23%
Follow IRMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
42.61 | 54.96 | 51.75 | 52.51 |
P/S ratio |
11.24 | 14.77 | 14.26 | 14.15 | |
P/FCF ratio |
69.75 | 79.57 | 53.50 | 51.82 | |
P/Operating CF |
129.59 | 208.96 | 148.43 | 205.66 | |
P/B ratio |
9.20 | 13.08 | 12.49 | 12.01 | |
Price to Tangible BV |
9.53 | 13.57 | 12.92 | 12.43 | |
EV/Sales |
10.54 | 14.16 | 13.61 | 13.47 | |
EV/EBITDA |
32.85 | 43.44 | 39.96 | 39.84 | |
EV/Operating CF |
33.93 | 47.56 | 40.56 | 42.84 | |
EV/FCF |
65.40 | 76.28 | 51.05 | 49.31 | |
Quick Ratio |
5.50 | 6.37 | 5.76 | 7.89 | |
Current Ratio |
6.64 | 7.98 | 7.13 | 9.46 | |
Net Debt/EBITDA |
(7.83) | (6.84) | (7.33) | (8.69) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.77 | 0.81 | 0.80 | 0.78 | |
Operating CF/Net income |
1.25 | 0.92 | 1.42 | 1.14 | |
Capex/Depreciation |
(3.30) | (1.09) | (1.03) | (1.08) | |
Research and Development Expense of Revenue |
3.18% | 3.52% | 4.35% | 3.21% | |
Selling, General and Administrative Expense of Revenue |
42.38% | 40.27% | 39.22% | 39.64% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
3.14% | 3.07% | 3.11% | 3.94% | |
Graham Net Nets |
0.08 | 0.05 | 0.06 | 0.06 | |
Graham Number |
17.04 | 17.21 | 17.96 | 18.05 | |
Earnings Yield |
2.35% | 1.82% | 1.93% | 1.90% | |
Free Cash Flow Yield |
1.43% | 1.26% | 1.87% | 1.93% | |
Revenue per Share |
1.67 | 1.78 | 1.72 | 1.60 | |
Operating CF per Share |
0.55 | 0.47 | 0.65 | 0.46 | |
Capex per Share |
(0.10) | (0.03) | (0.04) | (0.03) | |
Free Cash Flow per Share |
0.45 | 0.43 | 0.61 | 0.43 | |
Cash per Share |
4.44 | 4.02 | 4.41 | 4.62 | |
Shareholders Equity per Share |
7.73 | 7.44 | 7.71 | 7.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.73 | 7.44 | 7.71 | 7.96 | |
Free Cash Flow |
5.72 | 5.51 | 7.82 | 5.50 | |
Working Capital |
72.12 | 71.02 | 74.30 | 77.56 | |
Capital Expenditures |
(1.26) | (0.42) | (0.47) | (0.44) | |
Net Current Asset Value |
68.55 | 67.05 | 70.55 | 73.50 | |
EV/EBIT |
34.15 | 45.38 | 42.00 | 42.19 | |
Capex to Sales |
0.06 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
36.42 | 47.33 | 44.02 | 44.33 | |
| Other line items | |||||
Average Receivables |
12.11 | 12.11 | 13.06 | 12.06 | |
Average Payables |
1.87 | 1.86 | 2.39 | 1.88 | |
Average Inventory |
11.49 | 11.01 | 11.22 | 11.73 | |
Average Assets |
104.48 | 103.55 | 108.06 | 110.71 | |
Average Common Equity |
90.89 | 90.72 | 94.28 | 98.02 |
Columns are period end dates